Overview

A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)

Status:
Not yet recruiting

Trial end date:
2023-10-02

Target enrollment:

Participant gender:

Summary

This is a 24 week study to evaluate the efficacy and safety of budesonide and formoterol fumarate metered dose inhaler in adults and adolescents with inadequately controlled asthma.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Budesonide, Formoterol Fumarate Drug Combination